Home > Cancer and Treatments > Urologic Cancers

Prostate Cancer is the most commonly diagnosed cancer among men in the US. It usually grows slowly. Men who have it often die from other causes before the cancer kills them. Still, prostate cancer is one of the most common causes of cancer death in American men. The prostate cancer death rate is especially high among African American men. To learn more, please visit:

Prostate Cancer web pages

Advanced or Metastatic Prostate Cancer web pages
part of the Health Library on UofMHealth.org's website.

Prostate Cancer

There is hope, innovation and support available for those with prostate cancer U-M Comprehensive Cancer Center

Patient Care and Treatment
The Urologic Oncology Program follows a team approach to diagnosing and treating those with prostate cancer. Our patients have their situation discussed not only by our urologic oncologists and surgeons, but also by experts in radiation oncology and pathology. By having everyone involved, a personalized treatment plan is developed. All of this takes place in our Multidisciplinary Urologic Oncology Clinic.

The surgical team has expertise in nerve-sparing prostatectomy for prostate cancer. In addition, the program's urologists have expertise in minimally invasive surgery, robotic-assisted surgery. Learn more about robotic surgery by visiting the Robotic Surgery webpage on the UofMHealth.org website.

Support
Since our program is part of the U-M Comprehensive Cancer Center, our patients have access to Patient/Family Support Services. To fully understand what this means, please take time to visit the For Cancer Center Patients area of this website. We outline the services available to our patients at every point in their care.


Larry, a prostate cancer survivor, discusses his experience with the disease, and why he made the decision to particpate in a clinical study.

Clinical Trials and Research
The Urologic Oncology Program is the recipient of a $6.5 million Specialized Program of Research Excellence grant in prostate cancer, a George M. O'Brien Urology Research Center grant, a PO1 in prostate cancer metastasis to bone, and two T32 Urology Training Grants. Active laboratory programs include work in the areas of prostate cancer genetics, gene discovery, metastasis, biomarker discovery, therapeutic development, and prostate and bladder cell biology. Recently, research has expanded broadly into specific evaluation of quality-of-life outcomes analyses for localized and metastatic bladder and prostate cancers. Clinical trials involving gene therapy, chemotherapy, immunotherapy and targeted agents are available for prostate, bladder and renal-cell cancers.

Make an appointment/referral

To make an appointment, please call 734-647-8903. If you would like to refer a patient, please contact our M-Line service: 800-962-3555. For more information, visit our Make an Appointment web page.

Still have questions?

The nurses at Cancer AnswerLine™ have answers. Call 1-800-865-1125 and you'll get a personal response from one of our registered nurses, who have years of experience in caring for people with cancer.

back to top


Small Text SizeMedium Text SizeLarge Text Size
Adjust text size

Speak with a Cancer nurse: 1-800-865-1125